Manager × security

Casdin Capital, LLC RLAY holdings history

Who else holds this security? →

RELAY THERAPEUTICS INC · CUSIP 75943R102 · CIK 1534261

This is the oldest quarter open without an account, so changes against the quarter before it are withheld. Sign in to see them.
Citable facts

As of 2026-06-30, Casdin Capital, LLC reported 16.04M RLAY (shares), valued at $300.02M, or 15.02% of its reported non-derivative portfolio. Filed 2026-08-14.

Verify history & sources →
Portfolio weight and quantity history
Reported portfolio weight
15.02%
Shares
16.04M
16,035,240
Reported value
$300.02M
USD

Shares increased 11.21%; reported value increased 109.12%, and weight changed +4.16 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.

Left: % · Right: Shares · Independently scaled axes

Exact data and methodology

Axes scale independently; a crossing does not mean equal values. Weight uses each quarter's total reported non-derivative value. Same CUSIP; missing quarters are gaps, not zero. Revised history may include later disclosures.

QuarterWeightQuantitySource
Q2 202615.02%16,035,240SEC filing ↗Filed Aug 14, 2026
Q1 202610.86%14,418,574SEC filing ↗Filed May 15, 2026
Q4 20256.83%13,003,574SEC filing ↗Filed Feb 17, 2026
Q3 20254.94%11,341,381SEC filing ↗Filed Nov 14, 2025
Q2 20253.59%11,398,574SEC filing ↗Filed Aug 14, 2025
Q1 20251.95%9,098,574SEC filing ↗Filed May 15, 2025
Q4 20242.47%8,948,574SEC filing ↗Filed Feb 14, 2025
Q3 20244.37%9,251,108SEC filing ↗Filed Nov 14, 2024
Q2 20244.21%8,448,574SEC filing ↗Filed Oct 18, 2024Amended
Q1 20244.59%7,423,574SEC filing ↗Filed May 15, 2024
Q4 20238.02%7,387,943SEC filing ↗Filed Feb 14, 2024

History & evidence by quarter

QuarterWeightQuantityValueChange explainedSource
Q4 20238.02%7,387,943$81.34MThe prior quarter is outside the free window. Sign in for the comparison.SEC filing ↗
Filed Feb 14, 2024
Q1 20244.59%7,423,574$61.62MShares increased 0.48%; reported value decreased 24.25%, and weight changed -3.43 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed May 15, 2024
Q2 20244.21%8,448,574$55.08MShares increased 13.81%; reported value decreased 10.60%, and weight changed -0.38 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Oct 18, 2024
Q3 20244.37%9,251,108$65.50MShares increased 9.50%; reported value increased 18.90%, and weight changed +0.16 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Nov 14, 2024
Q4 20242.47%8,948,574$36.87MShares decreased 3.27%; reported value decreased 43.71%, and weight changed -1.90 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Feb 14, 2025
Q1 20251.95%9,098,574$23.84MShares increased 1.68%; reported value decreased 35.34%, and weight changed -0.52 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed May 15, 2025
Q2 20253.59%11,398,574$39.44MShares increased 25.28%; reported value increased 65.44%, and weight changed +1.64 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Aug 14, 2025
Q3 20254.94%11,341,381$59.20MShares decreased 0.50%; reported value increased 50.11%, and weight changed +1.35 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Nov 14, 2025
Q4 20256.83%13,003,574$110.01MShares increased 14.66%; reported value increased 85.82%, and weight changed +1.89 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Feb 17, 2026
Q1 202610.86%14,418,574$143.46MShares increased 10.88%; reported value increased 30.41%, and weight changed +4.03 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed May 15, 2026
Q2 202615.02%16,035,240$300.02MShares increased 11.21%; reported value increased 109.12%, and weight changed +4.16 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Aug 14, 2026
Casdin Capital, LLC · RELAY THERAPEUTICS INC

Take these holdings further.

This page includes 11 of 11 reported holdings. Sign in to look up the full history beyond 3 years, use advanced screening & filtering, download CSV, and get the complete set through the Akkru API.

  • Download CSV
  • Earlier quarters
  • Advanced screening & filtering
  • API & AI access
Already have an account?

+ New accounts get free API credits to explore data beyond ownership filings.

For AI agents & developers

The initial HTML of this page carries its exact data as script#research-data (JSON): values, units, scope, preview limits and SEC sources. Read it directly, no script or API key needed; script#research-access says what needs an account.

Without an account: the last 3 years, with the row caps stated on the page. A free account opens all history on file on these pages and the CSV of what a page shows. Rows beyond the caps and bulk retrieval go through the authenticated API / MCP.

MCP  https://api.akkrudata.ai/mcp

get_institutional_portfolio
{"cik":"1534261","quarter":"2026Q2","cusip":"75943R102"}

get_institutional_manager_history
{"cik":"1534261","page_size":100}

Connect to MCP with OAuth and follow the returned pagination. Credits and usage limits depend on the account.

MCP endpoint
https://api.akkrudata.ai/mcp
API / MCP documentation
/documents
llms.txt
/llms.txt
Sources, coverage & how to read this data

Figures are as reported to the SEC and merged with later amendments where Akkru could match them. Preview limits apply to what is listed, not to the totals, which come from the complete reported data. Nothing is zero-filled: a missing quarter or month is shown as missing.

13F reports quarter-end long positions in securities traded on US exchanges, filed by managers holding at least $100 million of such securities; it is not the manager's full portfolio, not assets under management, and value changes are not returns. Weights use the reported total value as denominator. Option rows show notional value, not premium or net exposure. Amendments are merged into the quarter when Akkru could match them.